Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00949325 · OUTCOME

Mean Overall Survival of Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma · Source last updated 2019-03-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Days
Interval / dispersion
Full Range
Time frame
up to 5 years

Analysis population: Subjects who received Temsirolimus MTD, 20 mg/m\^2 in Phase I of the study and all subjects in the Phase II study were included from both Phase I and Phase II of the study are included.

Groups in this outcome

Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2

All subjects who received at least one dose of temsirolimus at the MTD, 20 mg/M\^2 plus liposomal doxorubicin were included.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^216

Reported measurements

Source class 1
Values in Days · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2632Not reported501532Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        50
        upper Limit
        1532
        value
        632
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    units
    Participants
dispersion Type
Full Range
groups
  1. description
    All subjects who received at least one dose of temsirolimus at the MTD, 20 mg/M\^2 plus liposomal doxorubicin were included.
    id
    OG000
    title
    Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2
param Type
MEAN
population Description
Subjects who received Temsirolimus MTD, 20 mg/m\^2 in Phase I of the study and all subjects in the Phase II study were included from both Phase I and Phase II of the study are included.
reporting Status
POSTED
time Frame
up to 5 years
title
Mean Overall Survival of Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2
type
SECONDARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice